This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

被引：0

作者：

Dimopoulos, M. A. ^{[1
]}

Oriol, A. ^{[2
]}

Nahi, H. ^{[3
,4
]}

Miguel, J. S. ^{[5
]}

Bahlis, N. J. ^{[6
]}

Rabin, N. ^{[7
]}

Orlowski, R. ^{[8
]}

Komarnicki, M. ^{[9
]}

Suzuki, K. ^{[10
]}

Plesner, T. ^{[11
,12
]}

Samoilova, O. S. ^{[13
]}

Yoon, S. S. ^{[14
]}

Yehuda, D. B. ^{[15
]}

Richardson, P. G. ^{[16
]}

Goldschmidt, H. ^{[17
,18
]}

Reece, D. ^{[19
]}

Khokhar, N. ^{[20
]}

O'Rourke, L. ^{[20
]}

Chiu, C. ^{[20
]}

Qin, X. ^{[21
]}

Guckert, M. ^{[20
]}

Ahmadi, T. ^{[20
]}

Moreau, P. ^{[22
]}

机构：

[1] Univ Athens, Athens, Greece

[2] HGTiP, Inst Catala Oncol, Barcelona, Spain

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[5] Univ Navarra Clin, CIMA, Pamplona, Spain

[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[9] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Vejle Hosp, Vejle, Denmark

[12] Univ Southern Denmark, Vejle, Denmark

[13] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[14] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[15] Hadassah Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Princess Margaret Canc Ctr, CCRU, Toronto, ON, Canada

[20] Janssen Res & Dev, Spring House, PA USA

[21] Janssen Res & Dev, Horsham, PA USA

[22] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB2238

引用

页码：342 / 342

页数：1

共 50 条

[31] Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand M., III
Fonseca, Gustavo A.
Reece, Donna E.
Lee, Kim
Chung, Weiyuan
Agarwal, Amit
Bahlis, Nizar J.
BLOOD, 2020, 136
[32] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Plesner, Torben
Dimopoulos, Meletios A.
Oriol, Albert
San-Miguel, Jesus
Bahlis, Nizar J.
Rabin, Neil
Suzuki, Kenshi
Yoon, Sung-Soo
Ben-Yehuda, Dina
Cook, Gordon
Goldschmidt, Hartmut
Grosicki, Sebastian
Qin, Xiang
Fastenau, John
Garvin, Wendy
Carson, Robin
Renaud, Thomas
Gries, Katharine S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139
[33] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Stewart, A. Keith
Rajkumar, S. Vincent
Dimopoulos, Meletios A.
Masszi, Tamas
Spicka, Ivan
Oriol, Albert
Hajek, Roman
Rosinol, Laura
Siegel, David S.
Mihaylov, Georgi G.
Goranova-Marinova, Veselina
Rajnics, Peter
Suvorov, Aleksandr
Niesvizky, Ruben
Jakubowiak, Andrzej
San Miguel, Jesus F.
Ludwig, Heinz
Zojwalla, Naseem
Tonda, Margaret E.
Xing, Biao
Moreau, Philippe
Palumbo, Antonio
BLOOD, 2014, 124 (21)
[34] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
Moustafa, Muhamad Alhaj
Parrondo, Ricardo
Abdulazeez, Mays F.
Roy, Vivek
Sher, Taimur
Alegria, Victoria R.
Warsame, Rahma M.
Larsen, Jeremy
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Kapoor, Prashant
Fonseca, Rafael
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Reeder, Craig B.
Agrawal, Arshi
Chanan-Khan, Asher A.
Ailawadhi, Sikander
BLOOD, 2020, 136
[35] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M.
Lonial, S.
Palumbo, A.
White, D.
Grosicki, S.
Spicka, I.
Walter-Croneck, A.
Moreau, P.
Mateos, M. -V.
Magen, H.
Belch, A.
Reece, D.
Beksac, M.
Spencer, A.
Oakervee, H.
Taniwaki, M.
Roellig, C.
Wu, K. L.
Singhal, A.
San Miguel, J.
Matsumoto, M.
Katz, J.
Bleickardt, E.
Poulart, V.
Richardson, P.
HAEMATOLOGICA, 2015, 100 : 173 - 173
[36] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
Stewart, A. Keith
Siegel, David
Ludwig, Heinz
Facon, Thierry
Goldschmidt, Hartmut
Jakubowiak, Andrzej J.
Miguel, Jesus F. San
Obreja, Mihaela
Blaedel, Julie
Dimopoulos, Meletios A.
BLOOD, 2017, 130
[37] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
Shinsuke Iida
Tohru Izumi
Takuya Komeno
Yasuhito Terui
Takaaki Chou
Takashi Ikeda
Deborah Berg
Shinichi Fukunaga
Kenkichi Sugiura
Makoto Sasaki
International Journal of Clinical Oncology, 2022, 27 : 224 - 233
[38] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
Iida, Shinsuke
Izumi, Tohru
Komeno, Takuya
Terui, Yasuhito
Chou, Takaaki
Ikeda, Takashi
Berg, Deborah
Fukunaga, Shinichi
Sugiura, Kenkichi
Sasaki, Makoto
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
[39] Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, Miles
Cochrane, Tara
Khokhar, Nushmia Z.
Guckert, Mary
Qin, Xiang
Oriol, Albert
BLOOD, 2016, 128 (22)
[40] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Delimpasi, Sosana
Pour, Ludek
Auner, Holger W.
Dimopoulos, Meletios A.
Rappaport, Alon
Fortin, Lisa
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →